Phase 3 N=460 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.00; -1.40 percentage of glycosylated haemoglobin
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
Lymphoma
Primary: Complete Response Rate — 65 percentage of evaluable participants
N/A N=2 Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
Leukemia · Myelodysplasia · Acute Lymphocytic Leukemia
Primary: Number of Successful Unrelated Cord Blood (UCB) Transplants — 2 participants
Phase 2 N=50 Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 5.7 months
Phase 1 N=38 A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar
Healthy Volunteer
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Aleglitazar — 98.5; 113; 151 hours (h)*nanogram (ng)/milliliter (mL)
Phase 1 N=74 Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
Parkinson's Disease (PD)
Primary: Cmax - Maximum Plasma Concentration of Levodopa (Levodopa/Carbidopa) — 966.6; 1026.8; 1097.9; 1019.7 ng/mL
N/A N=1,615 TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD
Cardiac Implantable Electronic Device Infection
Primary: Major CIED Infection — 0.6; 1.0; 0.7 percentage of Participants — p=0.0023
Phase 2 N=14 Nicotine Vaccination and Nicotinic Receptor Occupancy
Nicotine Dependence
Primary: Mean of the Average Nicotine Binding % at Scan 1 and Scan 2 — 54.9; 49.1 percentage of average nicotine binding — p=<0.05
N/A N=16 A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder
Bi-polar II Disorder
Primary: Change From Baseline in Mean Beck Depression Inventory (BDI) Score at Week 2 — -13.01; -3.76 units on a scale — p=0.016
N/A N=780 A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)
Anemia, Kidney Disease, Chronic
Primary: Percentage of Participants Who Achieved a 3-month Hemoglobin Level Stabilization in the Range of 11-12 Grams Per Deciliter (g/dL) — 17.18 Percentage of participants
Phase 2 N=25 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Overall Response Rate — 20.0 percentage of participants
N/A N=104 Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement
Ventral Incisional Hernia
Primary: Hernia Recurrence Rate — 17.3 % of subjects with recurrent hernia
Phase 2 N=25 Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Phase 1 N=32 Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
Type 2 Diabetes (T2D)
Primary: Number of Participants Experiencing an Adverse Event (AE) — 12; 2; 4; 2 Participants
Phase 2 N=64 An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
Arteriovenous Fistula
Primary: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation by Week 12 Visit Based on Hemodialysis or Color-flow Doppler Ultrasound (CDUS) And Vascular Access…